| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Research Abstract |
Clinical studies with growth factor receptor tyrosine kinases (RTKs) inhibitors in cancer have met with a lot of promise and underscore the importance of this pathway in tumor biology. We present evidence for a novel intracellular signaling pathway linking RTK to the CDM Rac exchange factor DOCK4 via adaptor protein Grb2. In NIH3T3 cells, DOCK4 is required for PDGF dependent cell migration and PDGF receptorβ(PDGFRβ) endocytosis. In HCT116cells, DOCK4 is required for EGF-dependent cell migration and EGFR endocytosis. In addition, DOCK4 expression is increased in proportion to invasion depth and metastasis. These data may indicate that DOCK4 is a potential regulator of tumor progressio
|
